Such Pedro, Olivares José Manuel, Arias Lizbeth, Troels Berg Mette, Madera Jessica
Medical Strategy and Communication, H. Lundbeck A/S, Valby, 2500, Denmark.
Department of Psychiatry, Hospital Álvaro Cunqueiro, Health Research Institute Galicia Sur (IISGS), CIBERSAM, Vigo, Spain.
Neuropsychiatr Dis Treat. 2021 Jun 10;17:1881-1892. doi: 10.2147/NDT.S303292. eCollection 2021.
To obtain real-world evidence of functional improvements during atypical long-acting injectable (aLAI) therapy in recent-onset schizophrenia, an online survey was conducted to assess the impact of aripiprazole once-monthly injectable 400 mg (AOM 400; partial D receptor agonist) and paliperidone palmitate once-monthly (PP1M; injectable, full D receptor antagonist).
Psychiatrists provided data for their 2 most recent AOM 400 patients, 2 most recent PP1M patients. Survey included 2000 patient cases (1000 AOM 400; 1000 PP1M). Eligible patients were aged 18-35 years, had been diagnosed with schizophrenia within 5 years, received AOM 400 or PP1M continuously for ≥6 months according to approved labels (mean durations: 1.6 and 1.7 years with AOM 400 and PP1M, respectively). Assessments included Global Assessment of Functioning (GAF) Scale, Personal and Social Performance Scale, Positive and Negative Syndrome Scale, and Quality of Life Scale. GAF assessments were done retrospectively and also at the time of survey.
Baseline mean GAF scores were 43.3 and 43.8 for AOM 400 and PP1M, respectively, indicating serious symptoms/functional impairment in both groups. Mean improvements following AOM 400 and PP1M therapy were 19.7 and 16.3 points, respectively (final scores in mild functional impairment category). Other measures assessing symptoms/functionality/quality of life demonstrated the benefits of long-term aLAI therapy.
Schizophrenia patients with serious functional impairment prior to current aLAI treatment showed improvements in functional outcome after AOM 400 or PP1M therapy. These results suggest functional improvements with aLAIs are apparent not only in research but also real-world settings.
为获取近期发病的精神分裂症患者在接受非典型长效注射剂（aLAI）治疗期间功能改善的真实世界证据，开展了一项在线调查，以评估阿立哌唑每月注射400mg（AOM 400；部分D受体激动剂）和棕榈酸帕利哌酮每月注射一次（PP1M；注射用，完全D受体拮抗剂）的影响。
精神科医生提供其2例最近使用AOM 400的患者和2例最近使用PP1M的患者的数据。调查涵盖2000例患者病例（1000例AOM 400；1000例PP1M）。符合条件的患者年龄在18至35岁之间，在5年内被诊断为精神分裂症，根据批准的标签连续接受AOM 400或PP1M治疗≥6个月（平均疗程：AOM 400和PP1M分别为1.6年和1.7年）。评估包括功能总体评定量表（GAF）、个人和社会表现量表、阳性与阴性症状量表以及生活质量量表。GAF评估在调查时进行回顾性评定，同时也在调查时进行评定。
AOM 400和PP1M的基线GAF平均得分分别为43.3和43.8，表明两组均存在严重症状/功能损害。AOM 400和PP1M治疗后的平均改善分别为19.7分和16.3分（最终得分处于轻度功能损害类别）。其他评估症状/功能/生活质量的指标显示了长期aLAI治疗的益处。
在当前aLAI治疗前存在严重功能损害的精神分裂症患者在接受AOM 400或PP1M治疗后功能结局有所改善。这些结果表明，aLAI不仅在研究中，而且在真实世界环境中都能带来明显的功能改善。
